Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-06

Study Completion Date

2017-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 1 study evaluating the safety and maximum tolerated dose of Liothyronine (T3) in subjects with multiple sclerosis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label Study of Liothyronine in MS

NCT02506751

Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive

COMPLETED PHASE1

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03355365

Multiple Sclerosis

COMPLETED PHASE2

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540

Multiple Sclerosis

COMPLETED PHASE2

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

NCT00676156

Multiple Sclerosis

COMPLETED PHASE1

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

NCT01188811

Multiple Sclerosis, Chronic Progressive

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot, phase I, placebo controlled clinical trial of short-term high-dose thyroid hormone to promote remyelination in MS. Permanent clinical disability in MS is likely caused by the neuronal damage and degeneration that follows recurrent demyelination with progressive failure of remyelination. Thyroid hormone (TH) is required for central nervous system (CNS) myelination during development, and CNS remyelination in animal models of MS, a process similar to developmental myelination, has also been found to be promoted by TH. This study will ascertain the safety, tolerability and maximum tolerated dose of TH in people with MS, explore reliability for a potential signal of treatment efficacy and mechanism, and optimize procedures for a full scale clinical trial to evaluate the efficacy of pulsed TH for promotion of remyelination in MS.

The safety and tolerability of this treatment will be assessed using subjects' self-report of symptoms, the validated Hyperthyroid Symptom Scale (HSS), and blood pressure measurements. a

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Dose escalation with monitoring for safety and tolerability, as well as reliability of VEP testing.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double-blind, randomized, controlled

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liothyronine (cytomel)

Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week

Group Type ACTIVE_COMPARATOR

Liothyronine sodium

Intervention Type DRUG

Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.

Placebo

Subject will take matching placebo twice a day for one week

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Patient will receive a matching placebo to take twice daily for one week.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liothyronine sodium

Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.

Intervention Type DRUG

Placebo

Patient will receive a matching placebo to take twice daily for one week.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cytomel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of MS of any type
* Age 18 to 50 years
* Weight range 45-90 kg (100-200 lbs)
* Lesions on brain MRI

Exclusion Criteria

* History of hypo or hyperthyroidism and a normal TSH
* History of high blood pressure (hypertension) \[
* Resting blood pressure greater than 150/95, resting heart rate greater than 100
* History of coronary artery disease or clinically significant arrhythmia, clinically significant abnormalities on EKG
* History of diabetes
* History of anemia or renal (kidney) disease
* Clinically significant abnormalities on metabolic panel or serum hematocrit below 32 %
* History of atrophic gastritis
* History of anxiety disorder or bipolar disorder
* Serious psychiatric or medical conditions that would preclude reliable participation in the study
* Use of illicit substances or alcohol abuse
* Current use of fingolimod (Gilenya)
* Current or prior use of mitoxantrone (Novantrone)
* Current use of stimulants (methylphenidate, atomoxetine, dextroamphetamine,phentermine)
* Current use of any blood thinners such as warfarin or apixaban (Aspirin is ok)
* Medications which would metabolized faster in the presence of thyroid hormone (Insulin, oral hypoglycemic agents and oral anticoagulants)
* Severe head tremors (which would impair the ability to perform VEPs)
* Present or recent use of medications that could interact with the thyroid hormone (iodine containing agents such as kelp supplements, amiodarone, iodinated contrast given for CT or xray), P450 stimulants (phenytoin, carbamazepine, phenobarbital, and rifampin)
* Corrected visual acuity worse than 20/50 in either eye or other eye issues that would prevent reading of a standard eye chart
* Head tremors or other tremors that would prevent sitting relatively still for a vision test
* Patients taking proton pump inhibitors (PPIs) or H2 blockers will be excluded unless they can safely not take these medications during the week of study drug administration.
* Patients taking Ampyra (dalfampridine) will be excluded unless they can safely not take these medications during the week of study drug administration.
* Pregnancy, breastfeeding, or intention to become pregnant in the following month
* Inability to receive an MRI (e.g. implanted metal device)

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No